• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    $CLXT
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CBUS alert in real time by email

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor.

    "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said Nassim Usman, Ph.D., President & CEO of Totus Medicines. "With the promising results from our ongoing Phase 1 TOS-358 study and the recent strengthening of our leadership team - including the addition of Dr. Zelanna Goldberg as Chief Medical Officer - Totus is poised to emerge as a leader in the covalent small molecule space."

    "I am excited to join Totus Medicines and leverage my expertise in the biotech sector to support the advancement of our pipeline, which addresses critical unmet medical needs across multiple therapeutic targets," said Simon Harnest, MSc, BSc.

    Prior to joining Totus Medicines, Simon served as Chief Investment Officer at Metagenomi (NASDAQ:MGX), where he led successful private capital raises and the IPO process, contributing to over $1 billion in equity raised throughout his career with over 15 years of experience in the biotech sector. Prior to Metagenomi, Simon held the same role at Cellectis (NASDAQ:CLLS), where he directed the US IPO and capital markets strategy, as well as the spin-off and IPO of Calyxt (NASDAQ:CLXT) now Cibus (NASDAQ:CBUS). His background includes key positions at Trout Group and Trout Capital, specializing in investor relations for the life sciences industry. Simon holds a Master of Science in Public Health from the London School of Economics and a Bachelor of Science in Economics from the University of Westminster, London, UK.

    About Totus Medicines

    Totus Medicines is discovering and developing small molecule medicines using a novel DNA-encoded covalent library technology combined with artificial intelligence/machine learning (AI/ML). With the unprecedented ability to screen several hundred million drug candidates against multiple targets simultaneously, the company's novel platform can find drugs that are dramatically superior to molecules discovered through previous technologies, including drug candidates for currently undrugged and difficult to drug targets. Totus is developing TOS-358, a covalent PI3Kα inhibitor in a Phase 1 clinical trial and is developing potent and selective covalent inhibitors of several other targets internally and has a drug discovery partnership with Lilly.

    For more information, please visit totusmedicines.com and follow Totus on LinkedIn and Twitter/X.

    Contact:

    [email protected]

    External Contact:

    Brian Mullen

    LifeSci Advisors, LLC

    Managing Director

    [email protected]

    +1.203.461.1175 



    Primary Logo

    Get the next $CBUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBUS
    $CLLS
    $MGX
    $CLXT

    CompanyDatePrice TargetRatingAnalyst
    Cibus Inc.
    $CBUS
    7/29/2024$25.00Buy
    Alliance Global Partners
    Cibus Inc.
    $CBUS
    7/19/2024$22.00Buy
    Canaccord Genuity
    Metagenomi Inc.
    $MGX
    5/7/2024$10.00Buy
    H.C. Wainwright
    Metagenomi Inc.
    $MGX
    5/2/2024$16.00 → $6.00Overweight → Neutral
    JP Morgan
    Metagenomi Inc.
    $MGX
    3/5/2024Outperform
    TD Cowen
    Metagenomi Inc.
    $MGX
    3/5/2024$22.00Outperform
    BMO Capital Markets
    Metagenomi Inc.
    $MGX
    3/5/2024$16.00Overweight
    JP Morgan
    Metagenomi Inc.
    $MGX
    3/5/2024$23.00Buy
    Jefferies
    More analyst ratings

    $CBUS
    $CLLS
    $MGX
    $CLXT
    SEC Filings

    View All

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    10/17/25 7:00:21 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    10/16/25 7:05:06 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 6-K/A filed by Cellectis S.A.

    6-K/A - Cellectis S.A. (0001627281) (Filer)

    10/14/25 4:30:29 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL

     ○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months ○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status ○ In the target Phase 2 population, 100% patients became transplant eligible with 78% proceeding to transplant ○ Among 11 patients previously treated with all 3 targeted therapies (inotuzumab, blinatumomab, and CD19 CAR-T), 8 responded and 7 achieved MRD-neg

    10/16/25 3:19:23 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cibus and AgVayā Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing

    SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced its agreement with AgVayā, a strategic growth advisory firm that partners with leading innovators, to develop strategies and solutions for the Indian agriculture market. Together, the companies will define market strategies, build partnerships, and accelerate the introduction of Cibus' gene editing technologies into India's rice seed industry, supporting the development of more resilient and productive rice varieties that are critical to both India's agricultural economy and the global ri

    10/16/25 7:46:54 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

    Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today hosts a R&D Day in New York City. The Company's leadership team and key opinion leaders will present the full Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel in r/r B-ALL. Details of the Event: Date: Today, October 16, 2025Time: 08:30 – 10:30 a.m. ETFormat: In-person and live webcastWebcast: Join live via https://us0

    10/16/25 7:00:00 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

    4 - Cibus, Inc. (0001705843) (Issuer)

    12/14/23 5:10:06 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Cibus Global with a new price target

    Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

    7/29/24 7:49:52 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Canaccord Genuity resumed coverage on Cibus Global with a new price target

    Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00

    7/19/24 8:34:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    H.C. Wainwright initiated coverage on Metagenomi with a new price target

    H.C. Wainwright initiated coverage of Metagenomi with a rating of Buy and set a new price target of $10.00

    5/7/24 6:26:47 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Box Kimberly Ann

    4 - Cibus, Inc. (0001705843) (Issuer)

    9/26/25 9:30:15 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    New insider Box Kimberly Ann claimed no ownership of stock in the company (SEC Form 3)

    3 - Cibus, Inc. (0001705843) (Issuer)

    9/26/25 9:24:34 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    SEC Form 4 filed by Director Reid Laurence

    4 - Metagenomi, Inc. (0001785279) (Issuer)

    9/2/25 4:44:51 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Leadership Updates

    Live Leadership Updates

    View All

    Cibus Announces the Election of Kimberly A. Box to Board of Directors

    SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company developing and licensing advanced plant traits that enable higher yields, lower input costs, and more sustainable farming, today announced the election of Kimberly A. Box to its Board of Directors. "Kim brings to Cibus extensive leadership experience in technology and commercialization that will be invaluable as we sharpen our strategic commercialization efforts," said Mark Finn, Cibus Chairman. "Her understanding of market dynamics and experience in guiding innovation into scalable businesses will strengthen our strategic governance as we continue to drive long-term value c

    9/25/25 4:05:00 PM ET
    $CBUS
    $MGRC
    Agricultural Chemicals
    Industrials
    Diversified Commercial Services
    Consumer Discretionary

    Cibus CEO to Highlight Gene Editing's Role in Building Resilient Agriculture at UN Climate Week 2025

    SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will participate in a featured panel during UN Climate Week 2025 in New York City. The event, titled "Investing in a Resilient Future: Innovation, Data & Capital for Energy, Food, Water, and Climate Solutions", supported by Syntax Data, will be held on Tuesday, September 23rd at Midtown Loft, New York City, with a livestream available via LinkedIn. Dr. Beetham will join leaders from the United Nations Devel

    9/22/25 12:10:00 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Financials

    Live finance-specific insights

    View All

    Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call

    SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report second quarter 2025 financial results on Thursday, August 14, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Second Quarter 2025 Results Conference Call Event Date: Thursday, August 14, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-2483 (U.S.), +1-785-838-9284 (International)The conference ID "CIBUS" or 24287 will be required for en

    8/5/25 7:00:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

    Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025  Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025  AstraZeneca partnership: R&D activities are continuing to advance for the three programs initiated Appointment of Mr. André Muller as Director to Cellectis' Board of Directors Cash, cash

    8/4/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

    NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-343-5172 Inte

    7/28/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Metagenomi Inc.

    SC 13G - Metagenomi, Inc. (0001785279) (Subject)

    11/6/24 4:35:15 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Cellectis S.A. (Amendment)

    SC 13D/A - Cellectis S.A. (0001627281) (Subject)

    5/21/24 4:19:05 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Metagenomi Inc.

    SC 13G - Metagenomi, Inc. (0001785279) (Subject)

    5/10/24 6:40:45 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care